Ubs Group Ag Monte Rosa Therapeutics, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 59,399 shares of GLUE stock, worth $359,957. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,399

Previous 25,333 134.47%

Holding current value

$359,957

Previous $134,000 207.46%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.8 - $10.36 $163,516 - $352,923	34,066 Added 134.47%	59,399 $412,000
Q3 2024 Nov 14, 2024	BUY	$3.59 - $6.97 $7,320 - $14,211	2,039 Added 8.75%	25,333 $134,000
Q2 2024 Aug 13, 2024	SELL	$3.38 - $7.86 $60,431 - $140,528	-17,879 Reduced 43.42%	23,294 $87,000
Q1 2024 May 13, 2024	BUY	$4.26 - $8.46 $13,738 - $27,283	3,225 Added 8.5%	41,173 $290,000
Q4 2023 Feb 09, 2024	BUY	$2.5 - $5.93 $36,597 - $86,809	14,639 Added 62.8%	37,948 $214,000
Q3 2023 Nov 09, 2023	SELL	$4.78 - $7.22 $2,227 - $3,364	-466 Reduced 1.96%	23,309 $111,000
Q2 2023 Aug 11, 2023	BUY	$4.53 - $8.4 $60,561 - $112,299	13,369 Added 128.47%	23,775 $162,000
Q1 2023 May 12, 2023	BUY	$5.95 - $8.21 $6,896 - $9,515	1,159 Added 12.53%	10,406 $81,000
Q4 2022 Feb 08, 2023	BUY	$6.71 - $9.72 $62,047 - $89,880	9,247 New	9,247 $70,000
Q2 2022 Aug 10, 2022	SELL	$6.15 - $14.99 $180,859 - $440,825	-29,408 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$10.36 - $20.41 $270,893 - $533,680	26,148 Added 802.09%	29,408 $412,000
Q4 2021 Feb 14, 2022	BUY	$16.28 - $27.15 $53,072 - $88,509	3,260 New	3,260 $67,000

Others Institutions Holding GLUE

# of Institutions

107

Shares Held

53.8M

Call Options Held

276K

Put Options Held

15.9K

View Full List

About Monte Rosa Therapeutics, Inc.

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $283M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

More about GLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account